Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 07, 2015 12:27 AM ET

Biotechnology

Company Overview of Targazyme, Inc.

Company Overview

Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...

3200 County Road 104

Floresville, TX 78114

United States

Founded in 2005

Phone:

210-560-7689

Key Executives for Targazyme, Inc.

Co-Founder, Chairman and Chief Executive Officer
Co-Founder and Vice President of Manufacturing
Age: 58
Co-Founder and Vice President of Research
Senior Vice President of Regulatory Affairs & Quality Assurance
Age: 71
Senior Vice President of Development
Compensation as of Fiscal Year 2014.

Targazyme, Inc. Key Developments

Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use with Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation

Targazyme Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TZ101 to prevent and reduce the severity and incidence of graft vs. host disease (GVHD) in patients eligible for hematologic stem cell transplant. GVHD is a serious, life-threating complication of stem cell transplantation. Orphan drug status confirms the importance of Targazyme's novel treatment approach to prevent and reduce the incidence and severity of GVHD in patients with blood cancers where stem cell transplant is prescribed. TZ101 could potentially transform hematopoietic stem cell transplantation by reducing patient morbidity and mortality from GVHD, which occurs in a large percentage of these patients and is very difficult to manage clinically.

Targazyme, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014

Targazyme, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.

TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board

TargaZyme, Inc. announced that it has appointed Christopher Calhoun to its Business Advisory Board. Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
AveXis, Inc. United States
Warren Pharmaceuticals Inc. United States
Haptic Technologies United States
Regulome Corp. United States
Velcera, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Targazyme, Inc., please visit targazyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.